Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients

Randomized, double-blind, placebo-controlled study of 1,525 patients did not meet statistical significance on primary endpoint (progression to non-invasive ventilation or invasive mechanical ventilation or death) Data showed 38% reduction in mortality b... Biopharmaceuticals Eli Lilly, Incyte , baricitinib, OLUMIANT, COVID-19
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news